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Abstract 
Introduction—Majority of the work for establishing nitroglycerin (NTG)-induced migraine 
models in animals was done in rats, though recently some studies in mice were also reported. 
Different special formulations of NTG were investigated in various studies; however, NTG 
treated groups were often compared to simple saline treated control groups. The aim of the 
present studies was to critically assess the utility of a panel of potential outcome measures in 
mice by revisiting previous findings and investigating endpoints that have not been tested in 
mice yet.  
Methods—We investigated two NTG formulations, Nitrolingual and Nitro Pohl, at an 
intraperitoneal dose of 10 mg/kg, in comparison with relevant vehicle controls, and evaluated 
the following outcome measures: light aversive behaviour,  cranial blood perfusion by laser 
Doppler imaging, number of c-Fos- and neuronal nitrogen monoxide synthase (nNOS)-
immunoreactive neurons in the trigeminal nucleus caudalis (TNC) and trigeminal ganglia, 
thermal hyperalgesia and tactile allodynia of the hind paw and orofacial pain hypersensitivity.  
Results—We could not confirm previous reports of significant NTG-induced changes in 
light aversion and cranial blood perfusion of mice but we observed considerable effects 
elicited by the vehicle of Nitrolingual. In contrast, the vehicle of Nitro Pohl was apparently 
inert. Increased c-Fos expression in the TNC, thermal hyperalgesia, tactile allodynia and 
orofacial hypersensitivity were apparently good endpoints in mice that were increased by 
NTG-administration. The NTG-induced increase in c-Fos expression was prevented by 
topiramate but not by sumatriptan treatment. However, the NTG-induced orofacial 
hypersensitivity was dose dependently attenuated by sumatriptan.  
Discussion—Our results pointed to utilisable NTG formulations and outcome measures for 
NTG-induced migraine models in mice. Pending further cross-validation with positive and 
negative control drugs in these mouse models and in the human NTG models of migraine, 
these tests might be valuable translational research tools for development of new anti-
migraine drugs.  
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1 Introduction 
Migraine is a disabling headache disorder characterized by moderate to severe, intense 
throbbing or pulsating pain generally occurring on one side of the head and which may be 
aggravated by routine physical activity; other symptoms may include light or sound 
sensitivity, nausea and vomiting. Various forms of migraine affect approximately 18% of 
women and 6% of men (Estemalik & Tepper, 2013). Although acute treatment of migraine is 
well manageable by triptans, there are many patients who cannot tolerate triptans or would 
need preventive medication. However, efficacy and tolerability of the preventive 
armamentarium, including antiepileptics, such as topiramate and valproate, and beta 
adrenergic receptor blockers is unsatisfactory (Silberstein et al., 2012). Therefore, a great 
unmet need exists for novel effective, safe and well-tolerated pharmacotherapies of migraine.  
Although recent research has revealed numerous details of the mechanisms participating in 
migraine generation, the primary initiating phenomena, the underlying neural and vascular 
mechanisms and their interrelationships are not understood and are surrounded by serious 
debates on various proposed theories, such as the vascular-, the neural- and the neurogenic 
inflammation theory of migraine (Moskowitz, 1993; Messlinger, Fischer, & Lennerz, 2011; 
Ashina, 2012; Noseda & Burstein, 2013).  
In line with the lack of a well-established theoretical background, numerous models have 
been proposed as useful tools for testing novel antimigraine drug candidates in animals or in 
human pharmacodynamic studies. Out of these, the most widely studied and accepted one is 
the nitroglycerin (NTG)-induced model of migraine (Olesen & Jansen-Olesen, 2012). NTG 
administration causes an immediate headache, stronger in migraine sufferers than in healthy 
subjects, and a delayed migraine-like headache only in migraineurs (Thomsen, Kruuse, 
Iversen, & Olesen, 1994; Olesen, 2008; Ashina, Hansen, & Olesen, 2013). The immediate 
headache in healthy volunteers was significantly attenuated by sumatriptan (Iversen & 
Olesen, 1996) and the delayed headache incidence in migraineurs was reduced by valproate 
(Tvedskov et al., 2004a).  
The majority of the work for establishing NTG-induced migraine models in animals was done 
in rats detecting the effect by various outcome measures, such as increased cerebral- and more 
controversially meningeal blood flow or blood vessel diameters (Read, Manning, McNeil, 
Hunter, & Parsons, 1999; Srikiatkhachorn, Suwattanasophon, Ruangpattanatawee, & 
Phansuwan-Pujito, 2002; Gozalov, Jansen-Olesen, Klaerke, & Olesen, 2008; Greco et al., 
2011; Pryazhnikov et al., 2014), increase in c-Fos protein expression in the trigeminal nucleus 
caudalis (TNC) (Tassorelli & Joseph, 1995; Pardutz, Krizbai, Multon, Vecsei, & Schoenen, 
2000; Knyihar-Csillik et al., 2008; Ramachandran et al., 2012), increase in neuronal nitric 
oxide synthase (nNOS) protein expression in trigeminal ganglia (TRGs) and/or TNC (Pardutz 
et al., 2000; Srikiatkhachorn et al., 2002; Dieterle, Fischer, Link, Neuhuber, & Messlinger, 
2011), electrophysiological detection of increase in neuronal activity of TNC neurons (Jones 
et al., 2001; Koulchitsky, Fischer, & Messlinger, 2009) and hypersensitivity to pain either on 
the paw/tail or in the facial (trigeminal) region measured by  behavioural responses to 
chemical, mechanical or thermal stimuli (Tassorelli et al., 2003; Tassorelli, Greco, Wang, 
Sandrini, & Nappi, 2006; Di et al., 2015; Greco et al., 2015). Whereas the use of rats has 
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several advantages, there are also reasonable considerations in favour of utilising mice, such 
as better availability of transgenic animals or the need to use much lower amounts of 
expensive substances for in vivo studies. However, much more limited experience exists 
concerning the NTG model in mice: Recently reported data indicated that increased c-Fos 
expression (Bates et al., 2010; Markovics et al., 2012; Goloncser & Sperlagh, 2014), thermal 
hyperalgesia (Bates et al., 2010; Goloncser & Sperlagh, 2014) and mechanical allodynia of 
the paw (Bates et al., 2010; Pradhan et al., 2014) are utilisable outcome measures of NTG-
induced changes in mice. In addition, our previous study suggested that increased cranial 
blood flow and light aversive behaviour are also suitable endpoints to detect NTG-induced 
changes in mice (Markovics et al., 2012). The aim of the present studies was to critically 
assess a panel of utilisable outcome measures in mice by revisiting previous findings, as well 
as by adding endpoints that have not been tested in mice yet, e.g. nNOS expression in the 
TRG and TNC, as well as pain hypersensitivity of the face, which formally might be a more 
relevant indicator of migraine than paw hyperalgesia.  
There was another confounding factor in previous studies, which determined our goals. In 
various studies different formulations of NTG were used, which were composed either for 
infusing or for sublingual spray application in patients, and the exact compositions of these 
often remained elusive. Several different NTG formulations contain propylene glycol and 
ethanol or propylene glycol and glucose (e.g. Nitrocine - 
https://www.medicines.org.uk/emc/medicine/1889); others (e.g. Nitrolingual) have even more 
complex vehicle without description of the exact composition. Some relatively dilute aqueous 
solutions of NTG (Nitro Pohl and Nitronal) contain only 5% glucose and mild acidification. 
Some of the above mentioned constituents (e.g. ethanol) may be assumed not to be entirely 
inert in studies of central nervous system functions. Nevertheless, many previous studies 
compared the effects of formulated NTG to a saline group instead of using an appropriate 
vehicle control (Bates et al., 2010; Di et al., 2015; Srikiatkhachorn et al., 2002; Tassorelli et 
al., 2003; Tassorelli et al., 2006) and in lack of control vehicle we did the same in a previous 
study (Markovics et al., 2012) using Nitrolingual formulation of NTG. However, in the 
present studies, to establish well-controlled NTG models, we intended to use appropriate 
vehicle controls. For this purpose we clarified the composition of Nitrolingual and composed 
an appropriate vehicle for control experiments. In addition, we started the studies with 
investigating two different formulations, Nitrolingual and Nitro Pohl, which latter we 
considered as the possibly most inert one from the assortment.  
2 Methods 
2.1 Animals 
Male CD1 mice (N=48) weighing 22-28 g were used for cranial blood flow and 
immunohistochemistry studies to preserve comparability to a similar previous study 
(Markovics et al., 2012). They were bred in the Laboratory Animal House of the Department 
of Pharmacology and Pharmacotherapy of the University of Pécs. For the behavioural 
experiments, male NMRI mice (N=142) weighing 25-35 g were used. In our experience this 
strain is more tranquil and suitable for behavioural and particularly for reliable pain threshold 
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studies than the CD1 strain. NMRI mice were obtained from TOXI-COOP Zrt (Budapest, 
Hungary). The animals were housed under standardised conditions (22 ± 2 °C room 
temperature) with an artificial 12/12 h light/dark cycle (lights on 06.00–18.00 h, humidity 
55±15%). Food (ssniff® R/M-H autoclavable; ssniff Spezialdiäten GmbH, Germany) and tap 
water were available ad libitum. In all behavioural experiments, the animals were 
acclimatised to the laboratory for at least 30-60 min before testing and were used only once. 
Experiments were performed in accordance with EU Directive 2010/63/EU for animal 
experiments. All the procedures involving animals were reviewed and approved either by the 
Richter Institutional Animal Care and Use Committee or the Ethics Committee on Animal 
Research of the University of Pécs. The number of animals and intensities of noxious stimuli 
used were kept to the minimum necessary to demonstrate consistent effects of the drug 
treatments. 
2.2 Drug treatments and control vehicles 
Two NTG preparations were used: Nitrolingual aerosol and Nitro Pohl solution for infusion 
(both obtained from Pohl-Boshkamp GmbH, Germany). Nitrolingual aerosol was freshly 
sprayed out into a foil-coated bottle on each experimental day. The solution contains 
7.7 mg/ml NTG and was administered at a dosing volume of 1.3 ml/kg for a dose of 10 mg/kg 
intraperitoneally (i.p.). The vehicle control solution for Nitrolingual was clarified by data 
mining in patent literature (US 2011/0240508) and compounded at Gedeon Richter Plc. and 
comprised (in % w/w): Miglyol 812 (caprylic/capric triglyceride, Sasol Germany GmbH) 
77.3%, Ethanol (96% Ph Eur.) 20%, Imwitor 988 (glyceryl caprylate, Sasol Germany GmbH) 
2% and Peppermint oil (Sigma-Aldrich) 0.7%.  
One ampoule Nitro Pohl solution for infusion was freshly opened on each experimental day. 
The solution contains 1 mg/ml NTG and was administered at a dosing volume of 10 ml/kg for 
a dose of 10 mg/kg i.p. In addition to NTG, the aqueous Nitro Pohl solution contains 
49 mg/ml glucose monohydrate and its pH is set to be mildly acidic by dilute hydrochloric 
acid (pH 3-5.5 as declared by the manufacturer). Occasional pH testing of Nitro Pohl solution 
indicated pH of 3.8. As vehicle control for Nitro Pohl, we used Rindex 5 solution for infusion 
(Teva, Hungary), which has the following composition: glucose monohydrate 5500 mg (278 
mmol/l), NaCl 397 mg (68 mmol/l), KCl 26 mg (3.5 mmol/l), MgCl2·7H2O 10.2 mg (0.5 
mmol/l) and CaCl2 18 mg (1.25 mmol/l) in 100 ml aqueous solution (declared pH 3.5-6; 
measured pH 4.3). Various doses of sumatriptan succinate (synthesised at Gedeon Richter) 
were dissolved in physiological (0.9%) saline solution (“saline”) and administered 
subcutaneously (s.c.) at a dosing volume of 10 ml/kg. Doses were calculated for free base. 
Topiramate (synthesised at Gedeon Richter) 80 mg/kg was dissolved in saline and 
administered i.p. at a dosing volume of 10 ml/kg. For anaesthesia, urethane was purchased 
from Spectrum 3D (Debrecen, Hungary) and dissolved in saline. It was used only in non-
survival experiments.  
2.3 Other materials 
Materials required for immunohistochemistry were the following: paraformaldehyde (Molar 
Chemicals, Hungary), glycerol and ethylene glycol (Spectrum 3D, Debrecen, Hungary), 
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Diaminobenzidine (Sigma-Aldrich, Hungary; D5637), Triton X-100 and H2O2 (Sigma 
Chemical, Zwijndrecht, The Netherlands), normal goat serum (Sigma-Aldrich, Hungary), 
polyclonal antiserum raised against c-Fos (sc-52; Santa Cruz Biotechnology Inc., Santa Cruz, 
CA, USA), biotinylated goat anti-rabbit IgG and avidine-biotin complex (Vectastain Elite 
ABC Kit, Vector Laboratories, Burlingame, CA, USA), anti-nNOS antibody (Abcam, 
Cambridge, UK), EZ-DeWax Solution and Antigen Retrieval Citra Solution (Biogenex, 
Fremont, CA, USA), xylene, DPX and ethanol solutions (Merck, Leicester, UK). 
2.4 Study logistics 
Six types of studies were performed. In the first two studies, which included detection of light 
aversion and cranial blood flow, both NTG preparations were tried. However, based on the 
experience gained in these studies, the use of Nitrolingual was dismissed for the rest of the 
studies. Instead, in the immunohistochemistry studies and in the novel mouse orofacial pain 
test we carried out some pharmacological validation besides detecting the effects of NTG.  
2.5 Light aversion assay 
Light-aversive behaviour was examined in mice both in the early (0–30 min) and late phases 
(90–120 min) following administration of NTG. A modified light–dark box was custom 
made, similar to those used in recent publications (Recober, Kaiser, Kuburas, & Russo, 2010; 
Markovics et al., 2012). The mice (N=53) were individually tested in the light aversion 
chamber (60 cm length× 26 cm width× 29 cm height) with two equally-sized compartments: 
one brightly lit (1000 lux, thermal-neutral fiber optic source, Fiber-lite, Dolan-Jenner Inc., 
USA), painted white and lacking a top, the other not lit, painted black and fully enclosed. A 
small opening (7×7 cm) connected the two compartments. Two chambers were used in 
parallel to test a vehicle- and an NTG-treated mouse at the same time. After 1-hour 
conditioning period in the testing room, the animals were injected i.p. with NTG or vehicle 
and were immediately placed into the light-dark box. Two randomised experiments were 
performed with the two different formulations of NTG and their respective control vehicles 
(2x2 groups). In the experiment with Nitrolingual a third, physiological saline, group was also 
included. Initially 8 animals were dedicated to each group. However, in the Nitrolingual 
experiment the group sizes were extended to N=12-13 in a second run in order to draw 
reliable conclusions regarding presence or absence of difference from vehicle group with 
adequate statistical power. Both observation periods were equally 30 min long, which had 
been chosen on the basis of a series of previous experiments (Markovics et al., 2012). 
Following the early observation period, the mice were put back to their home cages and 
placed into the light–dark box again 90 min after treatment to see how they behave in the late 
period. The chamber was thoroughly cleaned and scrubbed with 70% ethanol between testing 
of each animal. All experiments were performed between 8.00 and 14.00 h. The experiments 
were recorded with a digital camera and evaluated later by an observer. The time spent in the 
light was measured with a stopwatch in each 5-min period and expressed in seconds. Finally, 
the percent time spent in the light compartment was calculated and plotted.  
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2.6 Cranial blood flow experiments 
Mice were anaesthetised with urethane (1.5 g/kg i.p.) and placed onto a heating pad 
maintained at 38 °C. A cannula was inserted into the trachea and mice were breathing 
spontaneously throughout the experiment. The head was fixed and the skin and connective 
tissues covering the cranium were carefully removed. A small piece of a black cloth with an 
opening of the size of the exposed area was placed onto the head to reduce background noise.  
The cranial blood perfusion was investigated using a non-invasive laser Doppler scanner 
(PIM II System, Perimed AB, Sweden) through the closed cranium. The scanning device was 
positioned 18 cm above the head and the scanned region was extended to the top surface of 
both hemispheres. The scanner measures an averaged total microcirculatory blood perfusion 
including blood flows in capillaries, arterioles, venules and shunting vessels of meninges and 
superficial cortex. In this way an overall mean cranial blood flow could be assessed. The 
scanning procedure lasting for duration of approximately 1 min was automatically repeated 
continuously. Control baseline monitoring measurements were repeated until the mean 
perfusion value had stabilised. Then an NTG preparation (10 mg/kg Nitrolingual or Nitro 
Pohl) or corresponding vehicles were injected i.p. and the post-dose recording lasted for 4 
hours, after which the animals were euthanized by overanaesthesia with i,p, injection of 
urethane. All four groups comprised six animals. Measurements from this instrument are 
expressed as arbitrary perfusion units. To enable comparison of results, perfusion changes 
were expressed as percentage of baseline measurement.  
2.7 Immunohistochemistry study of c-Fos and nNOS in TNC and TRG 
Four groups of six mice were injected i.p. either with NTG (3 groups with 10 mg/kg Nitro 
Pohl) or vehicle (10 ml/kg Rindex 5). Two groups treated with NTG received also treatment 
of sumatripan (2x5 mg/kg 30 min before and after NTG) or topiramate (80 mg/kg 30 min 
before NTG). Two hours following injection of NTG or vehicle, the mice were anaesthetised 
with 2 g/kg urethan (i.p.) and after induction of anaesthesia, within 5 minutes from urethane 
injection, they were perfused transcardially with 20 ml 0.1 M sodium phosphate-buffered 
saline (PBS; pH 7.6) followed by fixative (150 ml ice-cold 4% paraformaldehyde) solution. 
The whole brain with the rostral cervical spinal cord and TRGs was dissected and post-fixed 
for 24 h in 6% paraformaldehyde solution.  
To study the caudal division of the spinal trigeminal nucleus, the medulla oblongata caudal to 
the obex with the rostral cervical spinal cord was embedded in 4% agar gel. Starting at the 
obex, 20 µm coronal sections were cut on a Lancer Vibratome (Ted Pella Inc., Redding, CA) 
and serially collected in 3 wells so that each well received sections at 60 µm intervals 
throughout the rostro-caudal extent of the brainstem and the spinal cord. Then, they were 
placed into anti-freeze solution consisting of 30% glycerol, 20% ethylene glycol and 0.1 M 
sodium phosphate buffer, and stored at -20 °C until further use. The first two series of 
sections were used for c-Fos and nNOS immunohistochemistry, respectively, while the third 
was kept as a reserve.  
TRGs were dehydrated in 50 v/v%, 70 v/v%, 90 v/v%, and 100 v/v% ethanol solutions. 
Sectioning was carried out on paraffin-embedded accurately oriented and blocked samples. 
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Three series of five 4-µm-thick longitudinal sections each interspaced by 60 µm were 
collected and mounted on silan-pretreated slides and dried.  
2.7.1 Free floating immunohistochemistry for c-Fos in the TNC 
For c-Fos immunohistochemistry, sections were washed 6×10 min in PBS, followed by 
incubation in 0.5% Triton X-100 and in blocking buffer consisting of PBS and 2% normal 
goat serum, for 30 min respectively. Then sections were incubated overnight at room 
temperature in a polyclonal antiserum raised against c-Fos, diluted 1:500 in blocking buffer. 
After a wash in PBS, sections were treated with biotinylated goat anti-rabbit IgG diluted 
1:200 in PBS containing 2% normal goat serum for 2 h at 20 °C (Gaszner et al., 2009).  
Sections were rinsed in cold PBS, incubated in avidin–biotin complex for 1 h at 20 °C, and 
rinsed with PBS for 3×10 min and with Tris buffer (pH 7.6) for 10 min. Finally, they were 
treated with 0.05% diaminobenzidine (DAB) in the Tris buffer with 0.00003% H2O2; the 
latter reaction was controlled under a stereomicroscope and stopped with Tris buffer. After 
3×10 min washes in PBS, sections were mounted on gelatine-coated glass slides, air-dried, 
treated with xylene for 2×10 min and coverslipped with DPX mounting medium.  
2.7.2 Free floating immunohistochemistry for nNOS in the TNC 
For nNOS immunohistochemistry, sections were pretreated with 0.1 M PBS and 0.3% H2O2 
in methanol for 30 min. The samples were washed twice in 0.1 M PBS containing 1% Triton 
X-100 (PBS-T) and incubated in blocking buffer consisting of PBS-T and 10% normal rabbit 
serum, for 1 h at room temperature. Then the sections were kept overnight at room 
temperature in polyclonal anti-nNOS antibody at a dilution of 1:300 in PBS-T solution 
containing 2 % normal rabbit serum. Between several rinses in cold PBS-T, the sections were 
treated with biotinylated rabbit anti-goat IgG at a dilution of 1:600 and the 
immunocytochemical reaction was visualized by Vectastain ABC Elite kit for 2 hours at room 
temperature, respectively. Samples were stained with nickel ammonium-sulphate-intensified 
DAB. The sections were dried on air overnight on glass slides, and coverslipped with DPX 
mounting medium.  
2.7.3 Immunohistochemistry for c-Fos in the TRG 
For c-Fos immunohistochemistry, rehydration was carried out by treating the slides in xylene 
for 2×10 min, followed by rinses in absolute ethanol and 96 v/v%, 70 v/v%, 50 v/v%, 30 
v/v% ethanol solutions, respectively. Slides were then incubated in PBS for 3×10 min, 
followed by incubation in 0.5% Triton X-100 and in blocking buffer consisting of PBS and 
2% normal goat serum, for 30 min, respectively. Subsequently, sections were incubated 
overnight at room temperature in a polyclonal antiserum raised against c-Fos, diluted 1:100 in 
blocking buffer (Gaszner et al., 2009). The second day of the c-Fos immunohistochemistry 
protocol was carried out as described above for free floating TNC sections, except mounting. 
TRG preparations were dehydrated by rinsing in 30 v/v%, 50 v/v%, 70 v/v%, 96 v/v% ethanol 
solutions, and in absolute alcohol respectively, treated with xylene for 2×10 min coverslipped 
with DPX mounting medium.  
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2.7.4 Immunohistochemistry for nNOS in the TRG 
The paraffin embedded TRG sections on glass slides were deparaffinated by 2x5 min 
treatment with EZ-DeWax Solution. After rinsing in distilled water containing 50 mM Tris-
buffer solution, the tissues were treated with Antigen Retrieval Citra Solution for 15 min 
according to the supplier’s protocol. Sections were then encircled with a liquid blocker pap 
pen and stained as described above for TNC nNOS immunohistochemistry. 
2.7.5 Digital imaging, cell counting 
For each type of evaluation in TNC, approximately XX sections per animal interspaced by 60 
µm and belonging to the first and second cervical segments of the spinal cord were selected 
according to Sidmann et al (1971), then 5 good quality sections per animal were designated 
for quantitative evaluation. Immunoreactive neurons in laminae I-III were evaluated. Also 5 
longitudinal sections interspaced by 60 µm were selected from 6-8 sections covering the 
whole diameter of the ganglion for each type of evaluation in TRG. A random selection 
procedure was maintained throughout all experiments and all quantifications were performed 
by an experienced neuroanatomist blinded to group assignment of the samples. The contents 
of c-Fos in the TRG and TNC were determined by simple manual counting of all c-Fos-
positive cell nuclei in non-edited digital images. Digital images were taken with a Nikon 
Microphot FXA microscope equipped with a Spot RT color digital camera (Nikon, Tokyo, 
Japan). nNOS immunoreactive neurons were counted in the TRG and TNC under a Zeiss 
Axio Imager M2 microscope. For the TNC, the absolute number of immunoreactive neurons 
per section was counted. For the TRG, the number of immunoreactive neurons was expressed 
in percentage of total number of cell nuclei. The observed absolute and relative counts were 
summed and averaged in each animal. Evaluation of 1, 3 and 2 animals from the TRG c-Fos, 
TRG nNOS and TNC nNOS studies, respectively, had to be omitted due to improper staining 
or injured sample. However, omissions did not exceed 1 (N=5-6 remaining) in any groups.  
2.8 Thermal hyperalgesia of the paw measured with the hot plate test 
The hot plate test was performed on two groups of ten mice by using an electronically 
controlled hot plate apparatus (Ugo Basile, Italy, Model Code: DS-37) heated to 46.5 °C 
(±0.3 °C). Animals were placed into a glass cylinder of 24 cm diameter on the heated surface, 
and the time between placing of the animal on the hot plate and the occurrence of licking of 
hind paws or jumping off the surface was recorded as response latency. The cut-off time was 
60 s. The response latency was recorded 60 min before and 60, 120, 180 and 240 min 
following i.p. injection of NTG (10 mg/kg Nitro Pohl) or vehicle. Mice assigned to a vehicle- 
and an NTG-treated group (N=10 each) were treated and tested in parallel in a randomised 
arrangement without blinding. 
2.9 Mechanical allodynia of the paw measured with von Frey filaments 
We used a method essentially similar to that of Bates et al. (2010), except the strain of mice. 
Hind paw withdrawal thresholds were tested by von Frey filament stimulation of the plantar 
surface of hind paw using an up-and-down paradigm (Chaplan, Bach, Pogrel, Chung, & 
Yaksh, 1994). Mice were placed in plastic chambers with mesh metal floor and allowed a 
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habituation period of 30 min. A series of 10 von Frey hairs (Stoelting Co., USA) with 
incremental stiffness (ranging from 0.008 g to 2.0 g) was applied to the mid-plantar surface of 
the hind paw. The first testing filament had the stiffness of 0.16 g. A positive response was 
defined as licking, lifting or shaking of the paw upon stimulation. One trial comprised poking 
the paw five times with the same filament at few-second intervals. A trial was considered 
positive if the animal reacted at least twice. According to the up-and-down paradigm 
increasing or decreasing of the stiffness of the next filament by one step was dependent on 
negative or positive paw withdrawal response of the actual trial. The 50% paw withdrawal 
threshold (PWT expressed in grams) was determined from 5 critical test responses starting 
with the first positive response (Dixon, 1980). The experiments started with twenty mice. 
After a baseline measurement, animals with baseline threshold ≤0.6 g (N=4) were excluded 
from the study. The remaining animals (N=16) were assigned to a vehicle and an NTG treated 
group (N=8). NTG (10 mg/kg Nitro Pohl) or vehicle was injected and PWT was measured 60, 
120, 180 and 240 min later. Mice assigned to these two groups were treated and tested in 
parallel in a randomised arrangement without blinding. 
2.10 Orofacial pain sensitivity tested with von Frey filaments 
The mice were placed into a 9-cm-long restraining glass cylinder so that only the head poked 
out and allowed a habituation period of 5 min. The restrainer allowed head and forepaw 
movements but prevented the animals from turning in it. A von Frey filament of 0.4 g force 
was used (Stoelting Co., USA). The filament was applied to the whisker pad on right side of 
the snout 12 times at approximately 90° angle until bent (Krzyzanowska et al., 2011). The 
responses were recorded and scored as follows: uni- or bilateral forepaw swipes across the 
face (1 point), aggression/biting of the probe following stimulus (0.25 points) or clear 
withdrawal of the head from the stimulus (0.25 points). The points (accumulated in the 12 
trials) were summed for each animal separately for each testing time to give the overall 
“response score”. The experiments started with sixty mice. After a baseline measurement 
animals with a score ≥2 (N=7) were excluded. The remaining animals (N=53) were assigned 
to five groups (N= 10-11) and NTG (10 mg/kg Nitro Pohl, in four groups) or vehicle (one 
group) was injected i.p. Thirty minutes later various doses of sumatriptan (0.3-3 mg/kg) or 
saline (control) solution was injected subcutaneously to the NTG-treated animals and saline 
also to the vehicle-treated animals. Then von Frey testing was repeated at 60, 90 and 120 min 
post-NTG. Mice assigned to different groups were treated and tested in parallel in a 
randomised arrangement. The experimenter was blind to the treatment during testing.  
2.11 Data analysis and statistics 
For different outcome measures data were expressed either as absolute values or percentages 
of baseline values. Results are plotted as the mean ± standard error of the mean (SEM). 
Where repeated measurements were performed statistical significance of differences was 
tested by two-way analysis of variance (ANOVA) with repeated measures followed by 
Bonferroni’s post-test for time-matching samples. For immunohistochemistry data one-way 
ANOVA was performed after confirming normality of distribution by Kolgomorov-Smirnov 
test. In case of significance, all other groups were compared to NTG control by Dunnett’s 
post-test. A p value less than 0.05 was considered significant in all tests.  
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3 Results 
3.1 Light aversion assay 
Mice injected with saline did not exhibit any overt tendency of change with regards to the 
average time spent in the light compartment (‘light-time’) either within the early or the late 
phase following the injection, although their time spent in light was less in the late phase (Fig. 
1A-B). In contrast, the time spent in the light was significantly reduced by both Nitrolingual 
and its vehicle in the early phase observation period, suggesting rapid development of 
photophobia (Fig. 1A) elicited primarily by the solvent of Nitrolingual itself. Nevertheless, by 
the late phase there was no apparent difference in the light avoiding behaviour between the 
saline, Nitrolingual and vehicle groups (Fig. 1B). In the experiment with Nitro Pohl, apart 
from a moderate gradual decline of the light-time, the injection caused no overt effect either 
in the early or the late phase (Fig. 1C-D). Most importantly, we could not detect any 
significant differences between the NTG groups and their simultaneous vehicle controls in 
either experiment.  
3.2 Cranial blood perfusion 
Injection of Nitrolingual, as well as its vehicle initiated a progressive increase in the cranial 
blood perfusion as measured by laser Doppler scanning. The enhancement amounted 
approximately 20% by 120 min post dose and remained sustained till the end of the 4-hour 
observation period in both groups (Fig. 2A). Apart from the non-significant difference that the 
rise in cranial blood perfusion occurred somewhat faster in the Nitrolingual group, there was 
no overt difference between the changes elicited by Nitrolingual or its vehicle. In contrast, 
injection of Rindex, the vehicle for Nitro Pohl, caused no remarkable change in the cranial 
blood perfusion, apart from <5% decrease in the first hour, and there was no significant 
difference between Nitro Pohl and the corresponding vehicle group (Fig. 2B). Hence, again, 
we could not detect any significant effect of NTG compared to the relevant control groups. 
Therefore, having observed a remarkable effect with its solvent, we excluded Nitrolingual 
from our further studies.  
3.3 Immunohistochemistry for c-Fos and nNOS 
We combined verification of the effect of NTG with pharmacological validation by testing the 
sensitivity of this model to the abortive- and preventive- antimigraine drugs sumatriptan and 
topiramate, respectively. Quantification of c-Fos positive nuclei in the TNC indicated 
statistically significant two-fold increase after treatment with NTG (Nitro Pohl) compared 
with the vehicle control (Rindex) group (Fig. 3A). However, a statistically significant increase 
could not be detected in the TRG (Fig. 3B, ANOVA p=0.31). Compared to the NTG treated 
group, a high dose of sumatriptan (5 mg/kg, s.c.) administered before and after NTG injection 
did not reverse significantly the increase in c-Fos expression in TNC. Although an apparent 
trend towards normalisation might have been noticed, it was far from significance (Dunnett’s 
adjusted p=0.63). In contrast, pretreatment with topiramate (80 mg/kg, i.p.) completely 
prevented the NTG-induced increase in c-Fos expression in TNC, which effect was significant 
(Fig.3A; p=0.03).  
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Immunostaining for nNOS did not reveal any significant alteration induced by NTG injection 
or any effect of the antimigraine drugs. The number of nNOS positive cells showed rather low 
variability in the TNC but much higher in the TRG (Fig. 3C-D).  
3.4 Thermal hyperalgesia of the paw 
Intraperitonal injecton of neither the vehicle nor Nitro Pohl caused any signs of pain related 
behaviour suggesting peritoneal irritation. Hot plate latencies of vehicle-treated mice were 
very stable over time with repeated testing four times up to 240 minutes post dose (Fig. 4A). 
NTG injection caused a clear-cut hyperalgesia, manifested in reduced defensive response 
latency, which effect was maximal and statistically significant at 60 min post dose. Nearly 
complete recovery was apparent by 180 min and there was no sign of a delayed secondary 
wave of hyperalgesia (Fig. 4A).  
3.5 Mechanical allodynia of the paw  
Changes in tactile hind paw withdrawal thresholds showed similar time course of the effect of 
NTG to that seen in the hot plate test (Fig. 4B). Although the mechanical threshold data of the 
vehicle control group displayed larger variability (coefficient of variation) and lower stability 
as compared to hot plate results, the apparent effect was also larger resulting in statistically 
significant changes at 60 min and 120 min post dose. The thresholds at 180-240 min after 
injection clearly indicated a tendency towards recovery without any sign of a late phase 
secondary sensitisation.  
3.6 Orofacial pain sensitivity 
Repeated recording of orofacial pain scores indicated no overt change in the pain-related 
behaviour of vehicle-treated animals (Fig. 5). However, mice treated with NTG exhibited a 
significant increase in nocifensive behaviour, which peaked at 60 min post-NTG and was 
declining later. The observed time-course was apparently similar to that seen in the plantar 
pain tests. Having established relatively short duration of action of NTG in the paw 
hyperalgesia/allodynia tests, we did not extend the study duration of the orofacial allodynia 
testing further than 2 hours after NTG. Instead, we included three further groups for 
pharmacological validation by a dose-response study of sumatriptan. Administration of 
sumatriptan 30 min before the first post-NTG testing remarkably suppressed the pain 
behaviour of mice. The dose-response relationship was apparent and flat at 60 min post NTG 
as the lowest dose of 0.3 mg/kg sumatriptan caused profound (more than 50%) inhibition. 
However, the effect of sumatriptan was not statistically significant at later time-points as the 
NTG-treated control group started to decline and the reversing effect of sumatriptan remained 
only partial (Fig. 5).  
4 Discussion 
Altogether we investigated 9 outcome measures in 6 studies and confirmed the utility of 4 of 
these for detecting the effects of NTG in mice. These outcome measures are (1) c-Fos 
expression in the TNC, (2) thermal hyperalgesia of the paw, (3) mechanical allodynia of the 
paw and (4) orofacial pain sensitivity. These might be useful to predict anti-migraine 
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effectiveness of drugs or target related genetic manipulations, provided that their sensitivity to 
anti-migraine drugs is proven in pharmacological validation experiments. Effectiveness of a 
single dose of NTG to influence the first 3 of these endpoints in mice has been proven 
previously (Bates et al., 2010; Goloncser & Sperlagh, 2014). However, some pharmacological 
validation by using sumatriptan has been provided only for the paw allodynia and 
hyperalgesia (Bates et al., 2010). Therefore, we included some groups to perform validation 
of those mouse tests that had no previous pharmacological validation data at all, i.e. in the 
immunohistochemistry and the orofacial pain tests. Nevertheless, it is worth to note that 
validation for predictive power of such migraine models would require the use of several 
different abortive and preventive medications with clinical proof of effectiveness, such as 
triptans, topiramate, propranolol and CGRP antagonists (Ashina et al., 2013) as well as 
investigation of some clinically failed negative controls. Extensive validation of these models 
was beyond the scope of the present investigations but might be the subject of further studies.  
The protein product (c-Fos) of the proto-oncogene c-fos is a sensitive and widely applicable 
marker of neuronal activation in response to various stimuli and its enhanced expression in 
the TNC after NTG administration in rats has been reported by several groups (Tassorelli & 
Joseph, 1995; Pardutz et al., 2000; Knyihar-Csillik et al., 2008; Ramachandran et al., 2012). 
NTG-induced increase of nNOS protein expression in the TNC and TRG has also been 
demonstrated in rats (Pardutz et al., 2000; Srikiatkhachorn et al., 2002; Dieterle et al., 2011). 
Whereas we also proved the NTG-induced increase of c-Fos in the TNC, we could not 
confirm NTG-induced changes of nNOS expression in mice either in the TNC or in the TRG. 
Since nNOS inducing effects in rats were revealed by at least three different research groups, 
we may assume that the discrepancy can be a species specificity issue. Concerning NTG-
induced c-Fos induction in TRG, we did not observe any significant effect in mice and we did 
not find any preceding literature data assessing this parameter in rats. However, c-Fos also 
proved not to be a suitable pain marker in sensory neurons of dorsal root ganglia of rats in 
contrast with the phosphorylated extracellular signal-regulated kinase which was induced both 
in dorsal horn and in sensory neurons by painful interventions (Gao & Ji, 2009). Having a 
significant NTG-induced increase only for c-Fos in the TNC, our attempt for pharmacological 
validation can be meaningfully interpreted only with regards to this outcome measure. The 
NTG-induced increase in c-Fos expression was sensitive to pretreatment with topiramate, 
which completely prevented the effect of NTG. Although preventive treatment by repeated 
dosing would have better mimicked the clinical setting, in this preliminary validation 
experiment administration of a single high dose was sufficient. On the contrary, our mouse 
NTG model with c-Fos expression readout was apparently insensitive or weakly sensitive to 
sumatriptan, administered 30 min before and after NTG, which did not produce a significant 
effect. In rats, Ramachandran et al. (2012) observed partial reversal of NTG-induced c-Fos 
increase in the TNC, but that model used much lower dose of NTG (80 µg/kg) by intravenous 
(i.v.) infusion. It remains an interesting question whether this difference in sensitivity to 
sumatriptan treatment is the consequence of species difference or the different provoking dose 
of NTG. In brief, c-Fos expression in TNC induced by NTG at the dose of 10 mg/kg i.p. in 
mice might be an utilisable outcome measure for detecting the effect of preventive treatments.  
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Our findings with regards to thermal hyperalgesia and tactile allodynia of the paw were in 
good concordance with those of Bates et al. (2010), showing maximal thermal hyperalgesia at 
60 min and maximal or close to maximal tactile allodynia at 60-120 min post-NTG, and 
complete or partial recovery, respectively, by 4 hours post dose. Our results with the hot plate 
method showed greater stability but smaller percent reductions in latency than their results by 
the Hargraves method. On the other hand, the baseline thresholds in our tactile allodynia test 
in NMRI mice were more than two-fold higher than in their C57BL6 mice, which is in 
agreement with our unpublished experience on comparison of the two strains. However, 
starting from a higher control threshold, we observed also a greater NTG-induced drop in 
percentage terms, which provides a greater window for investigation of preventive effects. 
Here it is relevant to note that Pradhan et al. (2014) have shown the single dose (10 mg/kg 
i.p.) NTG-induced plantar allodynia of mice to be sensitive to both sumatriptan and 
topiramate, whereas the progressive sustained mechanical allodynia induced by repeated 
dosing was sensitive only to topiramate.   
Measurement of orofacial pain sensitisation has apparently greater construct validity with 
regards to modelling migraine than measurements in other somatic areas. It reflects 
sensitisation in the innervations field of the trigeminal nerve, which is believed to play a 
central role in migraine generation (Messlinger et al., 2011). Spontaneous migraine is often 
accompanied by cephalic cutaneous allodynia, though extracephalic (somatic) allodynia is 
also prevalent (Bigal et al., 2008; Lipton et al., 2008; Bernstein & Burstein, 2012). 
Occurrence of orofacial pain hypersensitivity after NTG injection has been demonstrated in 
rats (Di et al., 2015; Greco et al., 2015), but not in mice. Our results show that pain-related 
behaviour scoring in mice can be used to detect orofacial pain sensitising effect of NTG. This 
orofacial hyperalgesia had similar time course to the plantar hyperalgesia with maximum at 
60 minutes post NTG and a tendency of recovery afterwards. Furthermore, the NTG-induced 
orofacial hyperalgesia was significantly alleviated by sumatriptan administration. These data 
suggest, that  measurement of orofacial pain can also be a useful outcome measure for 
modelling NTG-induced migraine-like headaches in mice; and this model is sensitive to 
triptans, like the plantar hyperalgesia/allodynia (Bates et al., 2010). It remains to be answered 
by extensive pharmacological validation experiments, whether the orofacial and the plantar 
(or other somatic) hyperalgesia/allodynia elicited by NTG exhibit differences in their 
pharmacological sensitivity, which might become an argument for favouring orofacial over 
plantar testing, or they prove to carry equal information in terms of modelling migraine.  
We confirmed our previous finding (Markovics et al., 2012) that injection of Nitrolingual 
enhanced the cranial blood perfusion as measured by transcranial laser Doppler scanning over 
the hemispheres of mice. However, comparison of the results with the relevant vehicle 
indicated that the enhanced blood perfusion was not due to the effect of NTG but the vehicle 
itself caused such pronounced effect and there was no significant difference between 
Nitrolingual and its vehicle. Since the vehicle contains several pharmacologically active 
constituents, including ethanol and peppermint oil, its vasodilating effects might be attributed 
to these ingredients. Ethanol can cause vascular relaxation by activation of transient receptor 
potential (TRP) vanilloid 1 receptors and CGRP release (Nicoletti et al., 2008). Peppermint 
oil (which contains menthol and menthone) can cause vasodilation through CGRP release 
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caused by activation of the TRP ankyrin 1 and TRP menthol 8 receptors (Namer, Seifert, 
Handwerker, & Maihofner, 2005; Takaishi et al., 2012). More surprisingly, we could not 
demonstrate any remarkable effect of NTG on cranial blood perfusion when it was 
administered in an apparently inert vehicle (Nitro Pohl vs. Rindex 5), as neither the vehicle 
nor Nitro Pohl produced any overt change.  
It is unclear if this lack of effect is due to species differences or the administration route or the 
inability of the technique to detect NTG-induced changes, as it averages blood flows in 
different depths and vessels or other experimental conditions, such as anaesthesia. In rats, 
typically meningeal blood vessel diameters have been assessed by imaging techniques and 
local cortical blood flow measurements were performed by laser Doppler flowmetry under 
anaesthesia. Cortical blood flow measurements after i.v. administration of small NTG doses 
(20-60 µg/kg) indicated increased flow (Read et al., 1999; Gozalov et al., 2008). Increased 
cortical laser Doppler flow was reported also after a large (10 mg/kg) i.v. dose of NTG 
(Srikiatkhachorn et al., 2002). Meningeal arterial diameters indicated strong dilations after a 
small i.v. NTG dose (Gozalov et al., 2008). Nevertheless, after an i.p. dose of 10 mg/kg in rats 
opposite changes, i.e. increased diameter of cortical and decreased diameter of meningeal 
arterioles were observed (Pryazhnikov et al., 2014). Hence, a possible explanation for lack of 
effect of NTG is that opposing vascular changes mutually neutralised in the net perfusion that 
was measured by the laser Doppler scanning technique. The impact of anaesthesia might also 
be considered. Gozalov et al., (2008) and Srikiatkhachorn et al., (2002) reported NTG-
induced meningeal and cortical vasodilations in pentobarbital-anaesthetised rats, whereas 
Pryazhnikov et al. (2014) reported the opposing effects on cortical and meningeal arterioles in 
urethane- as well as ketamine-xylazine-anaesthetised rats. We also used urethane in our 
experiments, first, to reproduce the conditions of Markovics et al. (2012), a study comparing 
Nitrolingual to saline, second, to produce a stable and long-lasting anaesthesia with relatively 
preserved autonomic reflexes and cardiovascular tone (Janssen et al., 2004).   
In mice, measurements of cranial vascular effects are more difficult than in rats due to their 
smaller size. A study applying intravital microscopy in pentobarbital-anaesthetised mice 
found that, in contrast with rats, meningeal vasodilating effect of CGRP could be detected 
only after preconstriction with endotheline-1 (Gupta et al., 2006). However, we could not find 
any reports of NTG-induced changes in cranial circulation of mice. The transcranial laser 
Doppler scanning seemed to be a promising and relatively non-invasive approach in mice. 
Nevertheless, although this method was apparently suitable to detect probably 
ethanol+menthol-induced enhancement of cranial blood flow in mice, it did not reveal 
10 mg/kg i.p. NTG-induced changes in our experiments.  
Photophobia is a common accompanying symptom of migraine, and light-avoiding behaviour 
is considered as a relevant outcome measure mimicking the migraineous state in mice. Light 
aversion could be induced by intracerebroventricular CGRP treatment in transgenic mice 
sensitized to CGRP by overexpression of the human receptor activity modifying protein 1 
(hRAMP1) associated with functional CGRP receptors (Recober et al., 2009; Recober et al., 
2010). In a previous study we showed that Nitrolingual induced significant light aversion 
when compared to a saline-treated group (Markovics et al., 2012). Significant differences 
were seen at the end of the early as well as the late phase of the study. In the present study, the 
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light aversive behaviour of saline control animals was less fluctuating and significant light 
aversion of Nitrolingual-treated mice was apparent only in the early phase. However, it turned 
out that the light aversive behaviour was attributable to the vehicle of Nitrolingual, as the 
genuine vehicle-treated animals exhibited a similar pattern to that with Nitrolingual. 
Furthermore, comparison of Nitro Pohl to its relevant vehicle control did not reveal any 
significant NTG-induced effect either in the early or in the late phase of the study. Hence, 
according to the present findings, it was not the NTG which induced light aversion in mice 
but the vehicle of Nitrolingual.  
Doses and routes of administration of NTG varied between animal studies making the 
interpretation and comparison of the results difficult. We uniformly applied 10 mg/kg i.p. 
dose of NTG in all experiments. This dose selection was based on the report of Bates et al. 
(2010), who established in dose-response studies that this was the minimum dose essential for 
detecting overt hypersensitivity in both thermal hyperalgesia and mechanical allodynia tests in 
mice. The relevance of such large systemic NTG doses has been criticised as being 1000-fold 
higher than the doses provoking headache and migraine in volunteers and patients, 
respectively (Ramachandran et al., 2012; Jansen-Olesen, Tfelt-Hansen, & Olesen, 2013). In 
the human NTG model typically 2.4-10 µg/kg (0.12-0.5 µg/kg/min for 20 min) i.v. dose 
(Iversen & Olesen, 1996; Tvedskov, Tfelt-Hansen, Petersen, Jensen, & Olesen, 2010) or 
0.5 mg (≈8 µg/kg) sublingual dose (Juhasz et al., 2005) is applied. Advocates of low-dose 
NTG proposed 80 µg/kg (4 µg/kg/min for 20 min) i.v. infusion in rats. After this dose, 
increased c-Fos expression in the TNC was evident (Ramachandran et al., 2012); but pain 
hypersensitivity has not been demonstrated so far. However, oral bioavailability of NTG in 
rats was low (F=1.6%) and associated with fast elimination (T1/2=4 min) and strong first-pass 
effect (Yap & Fung, 1978). Several factors may contribute to that about 100-fold higher doses 
are needed in mice by i.p. administration to elicit pain hypersensitivity than the suggested i.v. 
dose in rats provoking c-Fos increase: (1) the first-pass effect may be also significant after i.p. 
administration (Lukas, Brindle, & Greengard, 1971), (2) allometric scaling between rats and 
mice might be an argument for higher doses in mice; and (3) the potential need for somewhat 
higher or longer exposures to elicit consistent pain hypersensitivity. In fact, almost all studies 
demonstrating NTG-induced pain hypersensitivity in healthy mice or rats used the dose of 10 
mg/kg, i.p. (Tassorelli et al., 2003; Tassorelli et al., 2006; Bates et al., 2010; Pradhan et al., 
2014; Di et al., 2015; Greco et al., 2015) or 15 mg/kg, i.p. (Goloncser & Sperlagh, 2014). The 
only exception applied 0.1 mg/kg i.p. dose and found short-lasting periorbital tactile threshold 
decrease in naïve rats (Oshinsky & Gomonchareonsiri, 2007). The time-course of headache 
ratings in healthy volunteers after 20-min-long infusion of NTG exhibits only an early peak, 
whereas that in migraine patients an early and a late peak. The second peak, the delayed 
headache, particularly if elicited by 0.5 µg/kg/min infusion rate, fulfils International Headache 
Society criteria of migraine (Tvedskov et al., 2004a; Tvedskov et al., 2004b). Our results in 
mice, in line with that of others (Bates et al., 2010; Goloncser & Sperlagh, 2014), displayed 
only an “early” peak at 60 min with a tendency towards recovery starting by 120 min. 
Assuming analogy with the human model this single peak in healthy mice may represent the 
early peak in healthy volunteers without a secondary headache generation. The time-course in 
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mice appears to be shorter than in rats, where the hyperalgesic effect is sustained beyond 4 
hours post NTG (Tassorelli et al., 2003; Di et al., 2015).  
There is a great interest in human models of migraine, which could be used as indicators of 
efficacy in early clinical development of anti-migraine drugs, particularly for prophylactics, 
for which proof-of-concept studies are very resource intensive (Tvedskov et al., 2004a; 
Tvedskov et al., 2004b). The human NTG model either in volunteers with detection of the 
early headache or in patients with the delayed migraineous headache could be a useful test. 
However, it is not unequivocally sensitive to all clinically proven preventive migraine drugs, 
probably depending on whether their targeted mechanisms are downstream or upstream from 
the NTG-induced effects in the migraine generation process. The NTG-induced early and late 
headache were both significantly reduced by valproate but were unaffected by pretreatment 
with clinically effective doses of propranolol (Tvedskov et al., 2004a; Tvedskov et al., 
2004b). This latter finding might ruin the confidence in using the human NTG model in early 
clinical studies for dose finding or proof of effectiveness. If it were proven in further 
validation experiments that pharmacological sensitivity of the rodent NTG models with any of 
the feasible outcome measures predicts the sensitivity of the human model, then the rodent 
model can be used as a pre-screening test for drug candidates and mechanisms that are worth 
to investigate in the human NTG model with high confidence.  
It is worth to note that the utilisable endpoints in rodents, either c-Fos in TNC or somatic 
and/or face allodynia/hyperalgesia, are different from the most important endpoint in 
volunteers or patients, which is reported (scored) headache. Although presence of allodynia 
has been detected in spontaneous migraine (Bigal et al., 2008), such measurements have not 
been reported from the human NTG experiments. Nevertheless, as the migraineous pain may 
be a manifestation of trigeminal or more universal pain hypersensitivity (Bernstein & 
Burstein, 2012), it is not unlikely that pharmacological sensitivity of the different endpoints 
used in rodents and human subject finally prove to be similar. Therefore, comparative 
validation by using distinguished positive and negative control drugs in the rodent and human 
NTG models might provide a good translational research tool supporting the development of 
new anti-migraine drugs with mechanisms liable to NTG-induced headache.   
NTG is believed to function as a nitrogen monoxide (NO) donor via an enzymatic reaction 
catalysed by the mitochondrial aldehyde dehydrogenase enzyme (Chen, Zhang, & Stamler, 
2002; Ignarro, 2002). In vascular smooth muscle cells, the released NO acts via the enzyme 
soluble guanylate cyclase (sGC) to stimulate the generation of cyclic guanosine-
monophosphate (cGMP) and elicit vasodilation (Miller & Megson, 2007). However, sGC 
stimulation without NO mediation by low concentrations of NTG has also been proposed 
(Kleschyov et al., 2003). Multiple data suggest involvement of endogenous NO production 
and stimulation of the NO – sGC pathway during migraine attack (Olesen, 2008). Another 
mechanism which certainly plays a role in migraine generation is the release of CGRP in the 
trigeminovascular system. CGRP antagonists proved to effectively alleviate migraine 
(Edvinsson, 2008; Karsan & Goadsby, 2015). There is an intricate interplay between NTG or 
NO and CGRP. It has been suggested that NO causes release of CGRP (Strecker, Dux, & 
Messlinger, 2002) and vice versa CGRP elicits NO release (Li, Vause, & Durham, 2008), 
though the data from different sources are not unequivocal as reviewed by Olesen (2008).  
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Recently, it was shown that CGRP per se is not algogenic but becomes algogenic only after 
NTG treatment (Capuano, Greco, Navarra, & Tringali, 2014).  
Release of CGRP and consequently increased regional or systemic plasma levels of CGRP 
were observed during headache phase of spontaneous migraine attacks (Goadsby, Edvinsson, 
& Ekman, 1990) and during NTG-induced migraineous attacks in patients (Juhasz et al., 
2003). Nevertheless, the results on CGRP plasma levels during migraine attack are 
controversial, and a study using intrapatient comparison design failed to find any increase in 
jugular and cubital vein plasma levels (Tvedskov et al., 2005). No overt increase in systemic 
CGRP levels was observed during the early headache phase after NTG either in healthy 
volunteers or patients (Ashina, Bendtsen, Jensen, Schifter, & Olesen, 2001; Juhasz et al., 
2003; Kruuse, Iversen, Jansen-Olesen, Edvinsson, & Olesen, 2010). Furthermore, while 
involvement of CGRP in NTG-induced hyperalgesia and c-Fos expression was proved in rats 
by the use of CGRP antagonists MK-8825 (Greco et al., 2013) and olcegepant 
(Ramachandran et al., 2014), olcegepant was ineffective in preventing the migraine attack in 
the patients induced by 20 min x 0.5 µg/kg/min infusion of NTG (Tvedskov, Tfelt-Hansen, 
Petersen, Jensen, & Olesen, 2010). These results could be interpreted in a way that the CGRP 
pathway is not involved in the human NTG model but is involved in the rat model either with 
the low-dose (4 µg/kg/min) infusion (Ramachandran et al., 2014) or the high-dose (10 mg/kg) 
i.p. injection (Greco et al., 2013) as well as in the natural human migraine. Therefore, the rat 
(or rodent) NTG models might be better in terms of predictive validity than the human NTG 
model. However, it should be noted that, in order to mimic an abortive paradigm, olcegepant 
was administered after the NTG infusion in the human study. Furthermore, olcegepant was 
effective in rats only by pre-treatment but not by post-treatment (Ramachandran et al., 2014). 
Therefore, investigating a CGRP antagonist (or antibody) in man also by pre-treatment would 
provide more reliable results with regards to presence or absence of involvement of CGRP in 
the early as well as the late headache.  
In summary, we proved that c-Fos expression in the TNC, as well as somatic and facial pain 
sensitisation, are potentially useful endpoints in the mouse for detecting NTG-induced 
changes and modelling migraine. Further work is needed to confirm the predictive validity of 
these mouse models by extensive cross-validation using drugs and pharmacological tools by 
pre-treatment in the human and mouse NTG models and by comparisons with effectiveness in 
migraine patients. We could not confirm the utility of nNOS expression in the TNC or TRG, 
and also failed to show NTG-induced light avoidance in mice. For detection of NTG-induced 
vascular changes either different methods are needed instead of transcranial laser Doppler 
scanning or the mouse is not an appropriate species. Investigation of NTG effects using 
relatively inert vehicles and by comparison with adequate vehicle controls is highly 
recommended to avoid false conclusions in preclinical studies of NTG.   
 
Acknowledgements 
This research was supported by the European Union and the State of Hungary, co-financed by 
the European Social Found in the framework of TÁMOP 4.2.4.A/2-11-1-2012-0001 (A2-
19 
 
JÁDJ-12-0228) ‘National Excellence Program’, National Brain Research Program 
(KTIA_NAP_13-1-2013-0001) A and B (Chronic Pain Research Group; KTIA_NAP_13-
2014-0022; Z. Helyes, 888819). BG was supported by OTKA PD 100706. The authors thank 
Dr. Zsófia Sáska (Gedeon Richter Plc) for clarifying the composition and compounding the 
vehicle control solution for Nitrolingual.  
 
	 	
20 
 
References 
Ashina, M. (2012). Vascular changes have a primary role in migraine. Cephalalgia, 32, 428-
430. 
Ashina, M., Bendtsen, L., Jensen, R., Schifter, S., & Olesen, J. (2001). Calcitonin gene-
related peptide levels during nitric oxide-induced headache in patients with chronic 
tension-type headache. European Journal of Neurology, 8, 173-178. 
Ashina, M., Hansen, J. M., & Olesen, J. (2013). Pearls and pitfalls in human pharmacological 
models of migraine: 30 years' experience. Cephalalgia, 33, 540-553. 
Bates, E. A., Nikai, T., Brennan, K. C., Fu, Y. H., Charles, A. C., Basbaum, A. I. et al. (2010). 
Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in 
mice. Cephalalgia, 30, 170-178. 
Bernstein, C. & Burstein, R. (2012). Sensitization of the trigeminovascular pathway: 
perspective and implications to migraine pathophysiology. Journal of Clinical 
Neurology, 8, 89-99. 
Bigal, M. E., Ashina, S., Burstein, R., Reed, M. L., Buse, D., Serrano, D. et al. (2008). 
Prevalence and characteristics of allodynia in headache sufferers: a population study. 
Neurology, 70, 1525-1533. 
Capuano, A., Greco, M. C., Navarra, P., & Tringali, G. (2014). Correlation between algogenic 
effects of calcitonin-gene-related peptide (CGRP) and activation of trigeminal 
vascular system, in an in vivo experimental model of nitroglycerin-induced 
sensitization. European Journal of Pharmacology, 740, 97-102. 
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994). Quantitative 
assessment of tactile allodynia in the rat paw. Journal of Neuroscience Methods, 53, 
55-63. 
Chen, Z., Zhang, J., & Stamler, J. S. (2002). Identification of the enzymatic mechanism of 
nitroglycerin bioactivation. Proceedings of the National Academy of Sciences U.S.A, 
99, 8306-8311. 
Di, W., Zheng, Z. Y., Xiao, Z. J., Qi, W. W., Shi, X. L., Luo, N. et al. (2015). Pregabalin 
alleviates the nitroglycerin-induced hyperalgesia in rats. Neuroscience, 284, 11-17. 
Dieterle, A., Fischer, M. J., Link, A. S., Neuhuber, W. L., & Messlinger, K. (2011). Increase 
in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after 
infusion of an NO donor. Cephalalgia, 31, 31-42. 
Dixon, W. J. (1980). Efficient analysis of experimental observations. Annual Review of 
Pharmacology and Toxicology, 20, 441-462. 
Edvinsson, L. (2008). CGRP blockers in migraine therapy: where do they act? British Journal 
of Pharmacology, 155, 967-969. 
Estemalik, E. & Tepper, S. (2013). Preventive treatment in migraine and the new US 
guidelines. Neuropsychiatric Disease and Treatment, 9, 709-720. 
Gaszner, B., Jensen, K. O., Farkas, J., Reglodi, D., Csernus, V., Roubos, E. W. et al. (2009). 
Effects of maternal separation on dynamics of urocortin 1 and brain-derived 
neurotrophic factor in the rat non-preganglionic Edinger-Westphal nucleus. 
International Journal of Developmental Neuroscience, 27, 439-451. 
21 
 
Gao, Y. J. & Ji, R. R. (2009). c-Fos and pERK, which is a better marker for neuronal 
activation and central sensitization after noxious stimulation and tissue injury? The 
Open Pain Journal, 2, 11-17. 
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990). Vasoactive peptide release in the 
extracerebral circulation of humans during migraine headache. Annals of Neurology, 
28, 183-187. 
Goloncser, F. & Sperlagh, B. (2014). Effect of genetic deletion and pharmacological 
antagonism of P2X7 receptors in a mouse animal model of migraine. The Journal of 
Headache and Pain, 15, 24. 
Gozalov, A., Jansen-Olesen, I., Klaerke, D., & Olesen, J. (2008). Role of K ATP channels in 
cephalic vasodilatation induced by calcitonin gene-related peptide, nitric oxide, and 
transcranial electrical stimulation in the rat. Headache, 48, 1202-1213. 
Greco, R., Bandiera, T., Mangione, A., Demartini, C., Siani, F., Nappi, G. et al. (2015). 
Effects of peripheral FAAH blockade on NTG-induced hyperalgesia-evaluation of 
URB937 in an animal model of migraine. Cephalalgia. 
Greco, R., Mangione, A., Siani, F., Blandini, F., Vairetti, M., Nappi, G. et al. (2013). Effects 
of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia, 34, 
594-604. 
Greco, R., Meazza, C., Mangione, A. S., Allena, M., Bolla, M., Amantea, D. et al. (2011). 
Temporal profile of vascular changes induced by systemic nitroglycerin in the 
meningeal and cortical districts. Cephalalgia, 31, 190-198. 
Gupta, S., Akerman, S., van den Maagdenberg, A. M., Saxena, P. R., Goadsby, P. J., & van 
den Brink, A. M. (2006). Intravital microscopy on a closed cranial window in mice: a 
model to study trigeminovascular mechanisms involved in migraine. Cephalalgia, 26, 
1294-1303. 
Ignarro, L. J. (2002). After 130 years, the molecular mechanism of action of nitroglycerin is 
revealed. Proceedings of the National Academy of Sciences U.S.A, 99, 7816-7817. 
Iversen, H. K. & Olesen, J. (1996). Headache induced by a nitric oxide donor (nitroglycerin) 
responds to sumatriptan. A human model for development of migraine drugs. 
Cephalalgia, 16, 412-418. 
Jansen-Olesen, I., Tfelt-Hansen, P., & Olesen, J. (2013). Animal migraine models for drug 
development: status and future perspectives. CNS Drugs, 27, 1049-1068. 
Janssen, B. J., De Celle, T., Debets, J. J., Brouns, A. E., Callahan, M. F., & Smith, T. L. 
(2004). Effects of anesthetics on systemic hemodynamics in mice. American Journal 
of Physiology: Heart and Circulatory Physiology, 287, H1618-H1624. 
Jones, M. G., Lever, I., Bingham, S., Read, S., McMahon, S. B., & Parsons, A. (2001). Nitric 
oxide potentiates response of trigeminal neurones to dural or facial stimulation in the 
rat. Cephalalgia, 21, 643-655. 
Juhasz, G., Zsombok, T., Jakab, B., Nemeth, J., Szolcsanyi, J., & Bagdy, G. (2005). 
Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide 
(CGRP) concentration and migraine headache during nitroglycerin induced migraine 
attack. Cephalalgia, 25, 179-183. 
Juhasz, G., Zsombok, T., Modos, E. A., Olajos, S., Jakab, B., Nemeth, J. et al. (2003). NO-
induced migraine attack: strong increase in plasma calcitonin gene-related peptide 
22 
 
(CGRP) concentration and negative correlation with platelet serotonin release. Pain, 
106, 461-470. 
Karsan, N. & Goadsby, P. J. (2015). Calcitonin gene-related peptide and migraine. Current 
Opinion in Neurology, 28, 250-254. 
Kleschyov, A. L., Oelze, M., Daiber, A., Huang, Y., Mollnau, H., Schulz, E. et al. (2003). 
Does nitric oxide mediate the vasodilator activity of nitroglycerin? Circulation 
Research, 93, e104-e112. 
Knyihar-Csillik, E., Mihaly, A., Krisztin-Peva, B., Robotka, H., Szatmari, I., Fulop, F. et al. 
(2008). The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of 
c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the 
effects of SZR-72 and kynurenic acid. Neurosci.Res, 61, 429-432. 
Koulchitsky, S., Fischer, M. J., & Messlinger, K. (2009). Calcitonin gene-related peptide 
receptor inhibition reduces neuronal activity induced by prolonged increase in nitric 
oxide in the rat spinal trigeminal nucleus. Cephalalgia, 29, 408-417. 
Kruuse, C., Iversen, H. K., Jansen-Olesen, I., Edvinsson, L., & Olesen, J. (2010). Calcitonin 
gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache 
in healthy volunteers. Cephalalgia, 30, 467-474. 
Krzyzanowska, A., Pittolo, S., Cabrerizo, M., Sanchez-Lopez, J., Krishnasamy, S., Venero, C. 
et al. (2011). Assessing nociceptive sensitivity in mouse models of inflammatory and 
neuropathic trigeminal pain. Journal of Neuroscience Methods, 201, 46-54. 
Li, J., Vause, C. V., & Durham, P. L. (2008). Calcitonin gene-related peptide stimulation of 
nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Research, 
1196, 22-32. 
Lipton, R. B., Bigal, M. E., Ashina, S., Burstein, R., Silberstein, S., Reed, M. L. et al. (2008). 
Cutaneous allodynia in the migraine population. Annals of Neurology, 63, 148-158. 
Lukas, G., Brindle, S. D., & Greengard, P. (1971). The route of absorption of intraperitoneally 
administered compounds. Journal of Pharmacology and Experimental Therapeutics, 
178, 562-564. 
Markovics, A., Kormos, V., Gaszner, B., Lashgarara, A., Szoke, E., Sandor, K. et al. (2012). 
Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-
induced trigeminovascular activation in mice. Neurobiology of Disease, 45, 633-644. 
Messlinger, K., Fischer, M. J., & Lennerz, J. K. (2011). Neuropeptide effects in the trigeminal 
system: pathophysiology and clinical relevance in migraine. The Keio Journal of 
Medicine, 60, 82-89. 
Miller, M. R. & Megson, I. L. (2007). Recent developments in nitric oxide donor drugs. 
British Journal of Pharmacology, 151, 305-321. 
Moskowitz, M. A. (1993). Neurogenic inflammation in the pathophysiology and treatment of 
migraine. Neurology, 43, S16-S20. 
Namer, B., Seifert, F., Handwerker, H. O., & Maihofner, C. (2005). TRPA1 and TRPM8 
activation in humans: effects of cinnamaldehyde and menthol. Neuroreport, 16, 955-
959. 
Nicoletti, P., Trevisani, M., Manconi, M., Gatti, R., De Siena, G., Zagli, G. et al. (2008). 
Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the 
trigeminovascular system of the guinea pig. Cephalalgia, 28, 9-17. 
23 
 
Noseda, R. & Burstein, R. (2013). Migraine pathophysiology: anatomy of the 
trigeminovascular pathway and associated neurological symptoms, cortical spreading 
depression, sensitization, and modulation of pain. Pain, 154 Suppl 1, S44-S53. 
Olesen, J. (2008). The role of nitric oxide (NO) in migraine, tension-type headache and 
cluster headache. Pharmacology & Therapeutics, 120, 157-171. 
Olesen, J. & Jansen-Olesen, I. (2012). Towards a reliable animal model of migraine. 
Cephalalgia, 32, 578-580. 
Oshinsky, M. L. & Gomonchareonsiri, S. (2007). Episodic dural stimulation in awake rats: a 
model for recurrent headache. Headache, 47, 1026-1036. 
Pardutz, A., Krizbai, I., Multon, S., Vecsei, L., & Schoenen, J. (2000). Systemic nitroglycerin 
increases nNOS levels in rat trigeminal nucleus caudalis. Neuroreport, 11, 3071-3075. 
Pradhan, A. A., Smith, M. L., McGuire, B., Tarash, I., Evans, C. J., & Charles, A. (2014). 
Characterization of a novel model of chronic migraine. Pain, 155, 269-274. 
Pryazhnikov, E., Kislin, M., Tibeykina, M., Toptunov, D., Ptukha, A., Shatillo, A. et al. 
(2014). Opposite reactivity of meningeal versus cortical microvessels to the nitric 
oxide donor glyceryl trinitrate evaluated in vivo with two-photon imaging. PLoS One, 
9, e89699. 
Ramachandran, R., Bhatt, D. K., Ploug, K. B., Hay-Schmidt, A., Jansen-Olesen, I., Gupta, S. 
et al. (2014). Nitric oxide synthase, calcitonin gene-related peptide and NK-1 receptor 
mechanisms are involved in GTN-induced neuronal activation. Cephalalgia, 34, 136-
147. 
Ramachandran, R., Bhatt, D. K., Ploug, K. B., Olesen, J., Jansen-Olesen, I., Hay-Schmidt, A. 
et al. (2012). A naturalistic glyceryl trinitrate infusion migraine model in the rat. 
Cephalalgia, 32, 73-84. 
Read, S. J., Manning, P., McNeil, C. J., Hunter, A. J., & Parsons, A. A. (1999). Effects of 
sumatriptan on nitric oxide and superoxide balance during glyceryl trinitrate infusion 
in the rat. Implications for antimigraine mechanisms. Brain Research, 847, 1-8. 
Recober, A., Kaiser, E. A., Kuburas, A., & Russo, A. F. (2010). Induction of multiple 
photophobic behaviors in a transgenic mouse sensitized to CGRP. 
Neuropharmacology, 58, 156-165. 
Recober, A., Kuburas, A., Zhang, Z., Wemmie, J. A., Anderson, M. G., & Russo, A. F. 
(2009). Role of calcitonin gene-related peptide in light-aversive behavior: implications 
for migraine. The Journal of Neuroscience, 29, 8798-8804. 
Sidman, R. L., Angevin, J. B. J., & Taber Pierce, E. (1971). Atlas of the Mouse Brain and 
Spinal Cord. Cambridge: Harvard University Press. 
Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012). 
Evidence-based guideline update: pharmacologic treatment for episodic migraine 
prevention in adults: report of the Quality Standards Subcommittee of the American 
Academy of Neurology and the American Headache Society. Neurology, 78, 1337-
1345. 
Srikiatkhachorn, A., Suwattanasophon, C., Ruangpattanatawee, U., & Phansuwan-Pujito, P. 
(2002). 2002 Wolff Award. 5 -HT2A receptor activation and nitric oxide synthesis: a 
possible mechanism determining migraine attacks. Headache, 42, 566-574. 
24 
 
Strecker, T., Dux, M., & Messlinger, K. (2002). Nitric oxide releases calcitonin-gene-related 
peptide from rat dura mater encephali promoting increases in meningeal blood flow. 
Journal of Vascular Research, 39, 489-496. 
Takaishi, M., Fujita, F., Uchida, K., Yamamoto, S., Sawada, S. M., Hatai, U. C. et al. (2012). 
1,8-cineole, a TRPM8 agonist, is a novel natural antagonist of human TRPA1. 
Molecular Pain, 8, 86. 
Tassorelli, C., Greco, R., Wang, D., Sandrini, G., & Nappi, G. (2006). Prostaglandins, 
glutamate and nitric oxide synthase mediate nitroglycerin-induced hyperalgesia in the 
formalin test. European Journal of Pharmacology, 534, 103-107. 
Tassorelli, C., Greco, R., Wang, D., Sandrini, M., Sandrini, G., & Nappi, G. (2003). 
Nitroglycerin induces hyperalgesia in rats – a time-course study. European Journal of 
Pharmacology, 464, 159-162. 
Tassorelli, C. & Joseph, S. A. (1995). Systemic nitroglycerin induces Fos immunoreactivity in 
brainstem and forebrain structures of the rat. Brain Research, 682, 167-181. 
Thomsen, L. L., Kruuse, C., Iversen, H. K., & Olesen, J. (1994). A nitric oxide donor 
(nitroglycerin) triggers genuine migraine attacks. European Journal of Neurology, 1, 
73-80. 
Tvedskov, J. F., Lipka, K., Ashina, M., Iversen, H. K., Schifter, S., & Olesen, J. (2005). No 
increase of calcitonin gene-related peptide in jugular blood during migraine. Annals of 
Neurology, 58, 561-568. 
Tvedskov, J. F., Tfelt-Hansen, P., Petersen, K. A., Jensen, L. T., & Olesen, J. (2010). CGRP 
receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-
induced migraine. Cephalalgia, 30, 1346-1353. 
Tvedskov, J. F., Thomsen, L. L., Iversen, H. K., Gibson, A., Wiliams, P., & Olesen, J. 
(2004a). The prophylactic effect of valproate on glyceryltrinitrate induced migraine. 
Cephalalgia, 24, 576-585. 
Tvedskov, J. F., Thomsen, L. L., Thomsen, L. L., Iversen, H. K., Williams, P., Gibson, A. et 
al. (2004b). The effect of propranolol on glyceryltrinitrate-induced headache and 
arterial response. Cephalalgia, 24, 1076-1087. 
Yap, P. S. & Fung, H. L. (1978). Pharmacokinetics of nitroglycerin in rats. Journal of 
Pharmaceutical Sciences, 67, 584-586. 
 
	  
25 
 
Figure captions 
Figure	1		
Effects of two different formulations of nitroglycerin (NTG; 10 mg/kg, i.p.) compared to 
vehicle controls in the light aversion test. Nitrolingual (NL) was compared to both a saline 
group and a solvent mimicking „NL vehicle” group (A, B). Nitro Pohl was compared to its 
corresponding vehicle, Rindex (C, D). Data are presented as mean ± SEM (N=12-13/group in 
A-B and 8/group in C-D) of percent time spent in the light compartment of the light-dark box. 
Results were evaluated separately in the early 0-30 min (A, C) and late 90-120 min phases (B, 
D) following NTG injection. Abscissas show the time after NTG injection. Asterisks show 
statistically significant differences compared to the saline group (*p<0.05, ** p<0.01, 
***p<0.001; two-way repeated measures ANOVA followed by Bonferroni test). There were 
no significant differences when NTG formulations were compared to their respective vehicle 
controls.   
Figure	2		
Effects of two different formulations of nitroglycerin (NTG 10 mg/kg, administered i.p. at 0 
min) compared to their respective vehicle controls on cranial blood perfusion measured by 
Laser Doppler scanning. Data are presented as mean ± SEM (N=6/group) of percentage 
change relative to the baseline recording. There were no significant differences when the 
different NTG formulations (Nitrolingual: NL and Nitro Pohl) were compared to their 
respective vehicle controls (two-way repeated measures ANOVA followed by Bonferroni 
test). 
Figure	3	
Effects of nitroglycerin (NTG; 10 mg/kg i.p.) compared to vehicle (Veh) controls on 
quantitative immunohistochemistry for c-Fos and nNOS in the trigeminal nucleus caudalis 
(TNC) and trigeminal ganglia (TRG), and the effects of sumatriptan (Sum; 2x5 mg/kg, s.c.) 
and topiramate (Topi; 80 mg/kg, i.p.) in mice injected with NTG.  Data are presented as mean 
± SEM (N=5-6/group). Asterisks show statistically significant differences compared to the 
NTG group (*p<0.05; one-way ANOVA followed by Dunnett’s test).  
Figure	4	
Effects of nitroglycerin (NTG; 10 mg/kg i.p.) compared to vehicle controls on thermal 
hyperalgesia (A) and mechanical allodynia (B) of the hind paw. Data are presented as mean ± 
SEM (N=10/group in A and 8/group in B). Abscissas represent the time after NTG injection. 
Asterisks show statistically significant differences (*p<0.05; **p<0.01; two-way repeated 
measures ANOVA followed by Bonferroni test).  
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Figure	5	
Effects of nitroglycerin (NTG; 10 mg/kg, i.p.) compared to vehicle controls (Veh+Veh) on 
orofacial pain elicited by tactile stimuli, and alterations of the NTG-induced facial allodynia 
by different doses of sumatriptan (0.3-3 mg/kg, s.c.; NTG+Sum). Data are presented as mean 
± SEM (N=10-11/group) Abscissa represents the time after NTG injection. Asterisks show 
statistically significant differences compared to the NTG+vehicle treated group (*p<0.05; 
**p<0.01; ***p<0.001; two-way repeated measures ANOVA followed by Bonferroni test). 
Arrows indicate the time of administration of drugs.  
